SCHEMBL19918206

SCHEMBL19918206

CCCCCCCCCCCCCCCNc1ccc2c(c1)Sc1cc(OC)ccc1N2C(=O)OC(C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 6/20 0.45
▸ SNCA P37840 2/20 0.42
▸ CNR2 P34972 3/20 0.39
▸ CNR1 P21554 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ GPR119 Q8TDV5 2/20 0.37
▸ ACHE P22303 1/20 0.36
▸ PIM1 P11309 2/20 0.36
▸ CSNK1D P48730 2/20 0.36
▸ CSNK1E P49674 2/20 0.36
▸ CLK1 P49759 2/20 0.36
▸ CLK3 P49761 2/20 0.36
▸ CSNK1G2 P78368 2/20 0.36
▸ DYRK1A Q13627 2/20 0.36
▸ MAP3K19 Q56UN5 2/20 0.36
▸ PIM3 Q86V86 2/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ DYRK1B Q9Y463 2/20 0.36
▸ CSNK1G3 Q9Y6M4 2/20 0.36
▸ GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29403748 1.00 BCHE (0.45) BCHESNCACNR2CNR1ALDH1A1
SCHEMBL19939646 0.93 BCHE (0.47) BCHESNCAALDH1A1PIM1CSNK1D
SCHEMBL19942820 0.89 BCHE (0.49) BCHESNCAALDH1A1ACHEPIM1
SCHEMBL17999664 0.87 SNCA (0.46) BCHESNCACNR2CNR1ALDH1A1
SCHEMBL30196318 0.83 BCHE (0.44) BCHESNCACNR2ALDH1A1PIM1
SCHEMBL19918236 0.83 BCHE (0.44) BCHESNCACNR2ALDH1A1PIM1
SCHEMBL30196015 0.83 BCHE (0.44) BCHESNCACNR2ALDH1A1PIM1
SCHEMBL21096627 0.83 BCHE (0.44) BCHESNCACNR2ALDH1A1PIM1
SCHEMBL29406787 0.83 BCHE (0.43) BCHESNCACNR2ALDH1A1PIM1
SCHEMBL19918228 0.83 BCHE (0.43) BCHESNCACNR2ALDH1A1PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295101-A1 THERAPEUTIC COMPOUNDS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2023-09-21 — — US disclosed
US-20230295101-A1 THERAPEUTIC COMPOUNDS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2023-09-21 — — US disclosed
US-11560360-B2 Therapeutic compounds ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2023-01-24 — — US disclosed
US-20200407333-A1 THERAPEUTIC COMPOUNDS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2020-12-31 — — US disclosed
US-10745366-B2 Therapeutic compounds ARIZON BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2020-08-18 — — US disclosed
US-20190185441-A1 THERAPEUTIC COMPOUNDS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2019-06-20 — — US disclosed
WO-2018039487-A1 THERAPEUTIC COMPOUNDS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-03-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200407333-A1 THERAPEUTIC COMPOUNDS CFTR, MC2R, RPS21 BCHE 2894/4885SNCA 1861/4885CNR2 1055/4885
US-11560360-B2 Therapeutic compounds CFTR, MC2R, RPS21 BCHE 2894/4885SNCA 1861/4885CNR2 1055/4885
US-20230295101-A1 THERAPEUTIC COMPOUNDS CFTR, C1R, FURIN BCHE 1829/4885SNCA 2990/4885CNR2 1023/4885
US-20190185441-A1 THERAPEUTIC COMPOUNDS CFTR, C1R, FURIN BCHE 1829/4885SNCA 2990/4885CNR2 1023/4885
US-10745366-B2 Therapeutic compounds CFTR, C1R, FURIN BCHE 1829/4885SNCA 2990/4885CNR2 1023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback